The COVID-19 pandemic that has swept around the world in early 2020 has changed our daily practice and habits. Fortunately, however, 2020 also brings its share of new approaches and therapeutic combinations as well as new therapies. These advances are improving the outcomes and quality of life of our patients across the spectrum of oncological diseases. This article summarises the latest oncological advances and novelties for 2020 in the following tumor entities : lung, breast, digestive, gynecological, urological and ENT
Le cancer broncho-pulmonaire (CBP) le 4ème cancer le plus répandu au niveau mondial après les cancer...
The year 2020 has been dominated by the coronavirus disease 2019 (COVID-19) pandemic, with important...
L´évérolimus est un inhibiteur mTOR ayant démontré une activité clinique dans plusieurs tumeurs soli...
Driven by highly specialized medicine, research and the quest for personalization of treatments, onc...
Medical oncologists are steering a difficult course during the COVID-19 pandemic between three oppos...
The main pharmacovigilance updates in 2020 are reviewed. Remdesivir in COVID-19: relatively safe but...
peer reviewedMedian survival of advanced pancreatic cancer is about three months. Unfortunately, che...
L’amélioration constante du pronostic des pathologies cancéreuses est le fruit des progrès réalisés ...
peer reviewedSoft tissue sarcomas account for 1% of all malignant tumours. Until a few years ago, do...
The standard of care of melanoma patients has evolved at a rapid pace with the advent of immune chec...
In 2017, data from large multicentre randomized controlled trials assessed the safety of minimally i...
peer reviewedOver the last decades, significant advances were make in basic research as concerns the...
International audienceExplorer l'efficacité du trilaciclib et de l'ALRN-6924 dans la prévention de l...
peer reviewedEpithelial ovarian cancer is frequently diagnosed at advanced-stage disease and chemoth...
Depuis le début des années 2000, les traitements anticancéreux oraux (TAO) sont en développement cro...
Le cancer broncho-pulmonaire (CBP) le 4ème cancer le plus répandu au niveau mondial après les cancer...
The year 2020 has been dominated by the coronavirus disease 2019 (COVID-19) pandemic, with important...
L´évérolimus est un inhibiteur mTOR ayant démontré une activité clinique dans plusieurs tumeurs soli...
Driven by highly specialized medicine, research and the quest for personalization of treatments, onc...
Medical oncologists are steering a difficult course during the COVID-19 pandemic between three oppos...
The main pharmacovigilance updates in 2020 are reviewed. Remdesivir in COVID-19: relatively safe but...
peer reviewedMedian survival of advanced pancreatic cancer is about three months. Unfortunately, che...
L’amélioration constante du pronostic des pathologies cancéreuses est le fruit des progrès réalisés ...
peer reviewedSoft tissue sarcomas account for 1% of all malignant tumours. Until a few years ago, do...
The standard of care of melanoma patients has evolved at a rapid pace with the advent of immune chec...
In 2017, data from large multicentre randomized controlled trials assessed the safety of minimally i...
peer reviewedOver the last decades, significant advances were make in basic research as concerns the...
International audienceExplorer l'efficacité du trilaciclib et de l'ALRN-6924 dans la prévention de l...
peer reviewedEpithelial ovarian cancer is frequently diagnosed at advanced-stage disease and chemoth...
Depuis le début des années 2000, les traitements anticancéreux oraux (TAO) sont en développement cro...
Le cancer broncho-pulmonaire (CBP) le 4ème cancer le plus répandu au niveau mondial après les cancer...
The year 2020 has been dominated by the coronavirus disease 2019 (COVID-19) pandemic, with important...
L´évérolimus est un inhibiteur mTOR ayant démontré une activité clinique dans plusieurs tumeurs soli...